The US Food and Drug Administration (FDA) has approved the first generic version of EpiPen and EpiPen Jr (epinephrine) auto-injector for the emergency treatment of allergic reactions.
Global specialty pharma company, Theramex, and private pharma company, Endoceutics, have entered into a definitive agreement for the exclusive licensing of Intrarosa (Prasterone) in Europe, Australia, Russia and the Ukraine.
The US Food and Drug Administration (FDA) has issued a warning to consumers about criminals who are forging warning letters, as though they have been written by the agency, in efforts to target individuals who are trying to purchase medicines online
Swedish based pharmaceutical development company, Kancera, has announced that unique blockers (antagonists) of the Fractalkine system have been patented, laying the foundations for the development of additional drug candidates.
The US Food and Drug Administration (FDA) has issued warnings to two Chinese drug manufacturers for violations of good manufacturing practice (GMP), according to a post from the Regulatory Affairs Professionals Society (RAPS).
CDMO, Recipharm, has acquired Sanofi’s manufacturing centre and business located in Holmes Chapel, which will provide the company with a platform to take advantage of the growing respiratory drug market.
The US Food and Drug Administration (FDA) has granted orphan drug designation to Crossject's treatment for status epilepticus (epileptic seizure lasting longer than five minutes), ZENEO Midazolam.
The Mundipharma network of independent associated companies has expanded its partnership with biopharma company Celltrion Healthcare to now include exclusive distribution rights to trastuzumab biosimilar, Herzuma, in seven EU markets.
A B2B online trading solution for active pharmaceutical ingredients (APIs) has been launched by Swiss-based Kemiex in partnership with credit insurance firm, Atradius.
Research from a team led by the Technical University of Munich (TUM) has uncovered a breakthrough in peptide chemistry that may enable the administration of peptide active agents orally.
A patient and a pharmacy level drug alert recall has been issued by the Medicines and Healthcare products Regulatory Agency (MHRA) for three specific lots of asthma inhalers as they may not deliver the full number doses
